WJCS  Vol.4 No.7 , July 2014
Early Postoperative Anticoagulation by Enoxaparin after Mechanical Aortic Valve Replacement
Abstract: Background: The use of low molecular weight heparin for early anticoagulation after mechanical aortic valve replacement is still a matter of debate even more that the early postoperative phase is associated with maximum of thrombo-embolic and bleeding risks. The objective of this study is to verify the efficacy and the safety of low molecular weight heparin for the early anticoagulation after mechanical aortic valve replacement. Methods and Results: It is a prospective study conducted over 6 months and interested 40 consecutive patients (32 male and 8 female) with a mean age 53.83 ± 16.93 years (19-75 years) who underwent a mechanical aortic valve replacement and received enoxaparin as bridging therapy between continuous unfractionated heparin and fully effective vitamin K antagonist therapy. There was no in-hospital death and no in-hospital thromboembolic events. We report 2 major bleeding events (5%). Conclusion: The use of low molecular weight heparin should be an alternative to explore for early anticoagulation after valve heart surgery and the results of our study must be verified by large randomized studies before drawing any hasty conclusions.
Cite this paper: Moutakiallah, Y. , Bamous, M. , Henaine, R. , Robin, J. , Obadia, J. and Ninet, J. (2014) Early Postoperative Anticoagulation by Enoxaparin after Mechanical Aortic Valve Replacement. World Journal of Cardiovascular Surgery, 4, 109-115. doi: 10.4236/wjcs.2014.47017.

[1]   Mok, C.K., Boey, J., Wang, R., Chan, T.K., Cheung, K.L., Lee, P.K., Chow, J., Ng, R.P. and Tse, T.F. (1985) Warfarin versus Dipyridamole-Aspirin and Pentoxifylline-Aspirin for the Prevention of Prosthetic Heart Valve Thromboembolism: A Prospective Randomized Clinical Trial. Circulation, 72, 1059-1063.

[2]   Cannegieter, S.C., Rosendaal, F.R. and Briet, E. (1994) Thrombo-Embolic and Bleeding Complications in Patients with Mechanical Heart Valve Prostheses. Circulation, 89, 635-641.

[3]   Saour, J.N., Sieck, J.O., Mamo, L.A. and Gallus, A.S. (1990) Trial of Different Intensities Of Anticoagulation in Patients with Prosthetic Heart Valves. The New England Journal of Medicine, 322, 428-432.

[4]   Hirsh, J., Dalen, E., Anderson, D.R., Poller, L., Bussey, H., Ansell, J., Deykin, D. and Brandt, J.T. (1998) Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. Chest, 114, 445S-469S.

[5]   Edmunds Jr., L.H., Clark, R.E., Cohn, L.H., Grunkemeier, G.L., Miller, D.C. and Weisel, R.D. (1996) Guidelines for Reporting Morbidity and Mortality after Cardiac Valvular Operations. The Journal of Thoracic and Cardiovascular Surgery, 112, 708-711.

[6]   Kulik, A., Rubens, F.D., Wells, P.S., Kearon, C., Mesana, T.G., Van Berkom, J. and Lam, B.K. (2006) Early Postoperative Anticoagulation After Mechanical Valve Replacement: A Systematic Review. The Annals of Thoracic Surgery, 81, 770-781.

[7]   Laffort, P., Roudaut, R., Roques, X., Lafitte, S., Deville, C., Bonnet, J. and Baudet, E. (2000) Early and Long Term (One-Year) Effects of the Association of Aspirin and Oral Anticoagulant on Thrombi and Morbidity after Replacement of the Mitral Valve with the St. Jude Medical Prosthesis: A Clinical and Transesophageal Echocardiographic Study. Journal of the American College of Cardiology, 35, 739-746.

[8]   Ionescu, A., Payne, N., Fraser, G., Giddings, J., Grunkemeier, L. and Butchart, E.G. (2003) Incidence of Embolism and Paravalvular Leak after St Jude Silzone Valve Implantation: Experience from the Cardiff Embolic Risk Factor Study. Heart, 89, 1055-1061.

[9]   Iung, B., Cormier, B., Dadez, E., Drissi, M.F., Tsezana, R., Viqiuer, E., Caviezel, B., Michel, P.L., Samama, M. and Vahanian, A. (1993) Small Abnormal Echos after Mitral Valve Replacement with Bileaflet Mechanical Prostheses: Predisposing Factors and Effect on Thromboembolism. The Journal of Heart Valve Disease, 2, 259-266.

[10]   Butchart, E.G., Lewis, P.A., Bethel, J.A. and Breckenridge, I.M. (1991) Adjusting Anticoagulation to Prosthesis Thrombogenicity and Patient Risk Factors. Recommendations for the Medtronic Hall Valve. Circulation, 84, III61-III69.

[11]   Heras, M., Chesebro, J.H., Fuster, V., Penny, W.J., Grill, D.E., Bailey, K.R., Danielson, G.K., Orszulak, T.A., Pluth, J.R., Puga, F.J., Schaff, H.V. and Larsonkeller, J.J. (1995) High risk of Thromboemboli Early after Bioprosthetic Cardiac Valve Replacement. Journal of the American College of Cardiology, 25, 1111-1119.

[12]   Weitz, J.I. (1997) Low Molecular Weight Heparins. The New England Journal of Medicine, 337, 688-698.

[13]   Wallentin, L., Goldstein, P., Armstrong, P.W., Granger, C.B., Adgey, A.A.J., Arntz, H.R., Bogaerts, K., Danays, T., Lindahl, B., Makijarvi, M., Verheugt, F. and Van de Werf, F. (2003) Efficacy and Safety of Tenecteplase in Combination with the Low Molecular Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital Setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Acute Myocardial Infarction. Circulation, 108, 135-142.

[14]   Petersen, J.L., Mahaffey, K.W., Hasselblad, V., Antman, E., Cohen, M., Goodman, S.G., Langer, A., Blazing, M.A., Le-Moigne-Amrani, A., De Lemos, J.A., Nessel, C.C., Harrington, R.A., Ferguson, J.J., Branwald, E. and Califf, R.M. (2004) Efficacy and Bleeding Complications among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non ST Segment Elevation Acute Coronary Syndromes: A Systematic Overview. JAMA, 292, 89-96.

[15]   Stellbrink, C., Nixdorff, U., Hofmann, T., Lehmacher, W., Daniel, W.G., Hanrath, P., Geller, C., Mügge, A., Sehnert, W., Schmidt-Lucke, C. and Schmidt-Lucke, J.A. (2004) Safety and Efficacy of Enoxaparin Compared with Unfractionated Heparin and Oral Anticoagulants for Prevention of Thromboembolic Complications in Cardioversion of Non Valvular Atrial Fibrillation: The Anticoagulation in Cardioversion Using Enoxaparin (ACE) Trial. Circulation, 109, 997-1003.

[16]   De Luca, I., Sorino, M., De Luca, L., Colonna, P., Del Salvatore, B. and Corlianò, L. (2005) Pre and Post-Cardioversion Transesophageal Echocardiography for Brief Anticoagulation Therapy with Enoxaparin in Atrial Fibrillation Patients: A Prospective Study with a 1-Year Follow-Up. International Journal of Cardiology, 102, 447-454.

[17]   Schmidt-Lucke, C., Paar, W.D., Stellbrink, C., Nixdorff, U., Hofmann, T., Meurer, J., Grewe, R., Daniel, W.G., Hanrath, P., Mügge, A., Klein, H.U. and Schmidt-Lucke, J.A. (2007) Quality of Anticoagulation with Unfractionated Heparin Plus Phenorocoumon for the Prevention of Thromboembolic Complications in Cardioversion for Non-Valvular Atrial Fibrillation. Sub-Analysis from the Anticoagulation in Cardioversion Using Enoxaparin (ACE) Trial. Thrombosis Research, 119, 27-34.

[18]   Cohen, M., Demers, C., Gurfinkel, E.P., Turpie, A.G., Fromell, G., Goodman, S., Laanger, A., Califf, R., Fox, K.A., Premmereur, J. and Bigonzi, F. (1997) A Comparison of Low Molecular Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. The New England Journal of Medicine, 337, 447-452.

[19]   Antman, E.M. (1996) Hirudin in Acute Myocardial Infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation, 94, 911-921.

[20]   Hull, R.D., Raskob, G.E., Hirsh, J., Jay, R.M., Leclerc, J.R., Geerts, W.H., Rosenbloom, D., Sackett, D.L., Anderson, C., Harrison, L. and Gent, M. (1986) Continuous Intravenous Heparin Compared with Subcutaneous Heparin in the Initial Treatment of Proximal Vein Thrombosis. The New England Journal of Medicine, 315, 1109-1114.

[21]   Schlitt, A., Buerke, M., Hauroeder, B., Peetz, D., Hundt, F., Bickel, C., Schaefer, I., Meyer, J. and Rupprecht, H.J. (2003) Fondaparinux and Enoxaparin in Comparison to Unfractionated Heparin in Preventing Thrombus Formation on Mechanical Heart Valves in an Ex-Vivo Rabbit Model. Thrombosis and Haemostasis, 90, 245-251.

[22]   Kovacs, M.J., Kearon, C., Rodger, M., Anderson, D.R., Turpie, A.G.G., Bates, S.M., Desjardins, L., Douketis, J., Kahn, S.R., Solymoss, S. and Wells, P.S. (2004) Single-Arm Study of Bridging Therapy with Low-Molecular-Weight Heparin for Patients at Risk of Arterial Embolism Who Require Temporary Interruption of Warfarin. Circulation, 110, 1658-1663.

[23]   Douketis, J.D., Johnson, J.A., Alexander, G. and Turpie, A.G. (2004) Low Molecular Weight Heparin as Bridging Anticoagulation during Interruption of Warfarin: Assessment of a Standardized Periprocedural Anticoagulation Regimen. Archives of Internal Medicine, 164, 1319-1326.

[24]   Montalescot, G., Polle, V., Collet, J.P., Leprince, P., Bellanger, A., Gandjbakhch, I. and Thomas, D. (2000) Low Molecular Weight Heparin after Mechanical Heart Valve Replacement. Circulation, 101, 1083-1086.

[25]   Fanikos, J., Tsilimingras, K., Kucher, N., Rosen, A., Hieblinger, M. and Goldhaber, S. (2004) Comparison of Efficacy, Safety, and Cost of Low Molecular Weight Heparin with Continuous Infusion Unfractionated Heparin for Initiation of Anticoagulation after Mechanical Prosthetic Valve Implantation. American Journal of Cardiology, 93, 247-250.